Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: fenn nc. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP. Tahk S, et al. Among authors: fenn nc. J Hematol Oncol. 2021 Sep 27;14(1):155. doi: 10.1186/s13045-021-01163-6. J Hematol Oncol. 2021. PMID: 34579739 Free PMC article.
Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP, Subklewe M. Schmitt S, et al. Among authors: fenn nc. Front Immunol. 2020 Nov 12;11:602802. doi: 10.3389/fimmu.2020.602802. eCollection 2020. Front Immunol. 2020. PMID: 33281829 Free PMC article.
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS. Braciak TA, et al. Among authors: fenn nc. Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018. Oncoimmunology. 2018. PMID: 30228941 Free PMC article.
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.
Schiller CB, Braciak TA, Fenn NC, Seidel UJ, Roskopf CC, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS. Schiller CB, et al. Among authors: fenn nc. Oncotarget. 2016 Dec 13;7(50):83392-83408. doi: 10.18632/oncotarget.13110. Oncotarget. 2016. PMID: 27825135 Free PMC article.